Press Release: ELISA/ACT® Biotechnologies Announces the Return of Clifford Materials Reactivity Tests (CMRT)

Press Release

ELISA/ACT® Biotechnologies Announces the Return of Clifford Materials Reactivity Tests (CMRT).

The leading test to identify reactivity to dental and orthopedic materials is once again available.

Sterling, VA – ELISA/ACT Biotechnologies is pleased to announce that the CMRT (Clifford Materials Reactivity Test) is once again available. CMRT has been a vital tool for biological dentists since its introduction over 30 years ago. The loss of the Walter Clifford, the scientist who developed the test, and the closure of his lab led to CMRT tests being unavailable for almost a year.

Each of us possesses unique chemical sensitivities. A substance which causes little or no reaction in one individual can prove harmful to another. Since these effects vary in each of us, it is vital that these material sensitivities be considered when choosing dental and other materials for use in the body.

The CMRT available through ELISA/ACT Biotechnologies offers dentists and physicians extensive information about their patient’s individual sensitivities so that the most suitable materials can be chosen and used in their treatments. CMRT looks for sensitivities to 94 chemical groups and correlates the reactions with a database of over 17,000 products.

Dr. Russell Jaffe, Founder of ELISA/ACT Biotechnologies, says “This test provides valuable, actionable information that is not available elsewhere. I had great respect for Jess (Walter Clifford) and I am so pleased to be able to bring back the Clifford test, just as he had offered it.”

To learn more about the CMRT (Clifford Materials Reactivity Test) visit or contact ELISA/ACT Biotechnologies at 800.553.5472 or Healthcare practitioners looking to order testing can open an EAB account online here.

About ELISA/ACT Biotechnologies

ELISA/ACT Biotechnologies® (EAB) is the exclusive provider of 2 advanced tests of immune response – lymphocyte response assay (LRA by ELISA/ACT) tests – the gold standard in delayed hypersensitivity testing and CMRT – the most comprehensive test of reactivity to dental and orthopedic materials. Additionally, only EAB offers least risk, best outcome interpretation of key Predictive Biomarkers.

Built on a strong foundation of patented technology, patient-friendly guidance, value-added support, and proven results, EAB will provide you with a successful plan to determine and address the causes of chronic disease and immune system dysfunction and restore overall health.

For over 30 years, our clinically proven, proprietary tests and individualized treatment plans have been used successfully in managing chronic autoimmune and immune dysfunction syndromes and guiding safer material selections.